Trial Profile
A Prospective, Randomized and Non-randomized, Controlled, Single-blind and Open-label, Dose-finding, Multi-center, Parallel Group Study of Safety/Efficacy of KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs KUR-113 (Primary)
- Indications Intervertebral disc degeneration
- Focus Therapeutic Use
- Acronyms STRUCTURE
- Sponsors Kuros Biosurgery
- 27 Dec 2023 Results presented in the Kuros Biosciences Media Release.
- 12 Oct 2023 According to a Kuros Biosciences media release, Chris Fair has been leading the commercial and operational teams to achieve completion of enrollment in this trial.
- 12 Oct 2023 According to a Kuros Biosciences media release, trial is expected to complete ahead in the final quarter of 2023.